A Phase 3B, Randomized, Open-label Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared with a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Latest Information Update: 05 Oct 2021
At a glance
- Drugs Emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Primary) ; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Acronyms STaR
- Sponsors Gilead Sciences
- 19 Nov 2020 Results estimating the annual cost of treatment for DOR/TDF/3TC compared with the STR of rilpivirine/tenofovir/emtricitabine presented at the 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 14 Oct 2019 Results of pooled analysis from 8 phase III trials (CTP 4999, 55400,55093,195806,228352,229699,263351 and 263352 )published in the Clinical Infectious Diseases
- 01 Mar 2014 Results published in the JAIDS.